Intensive insulin therapy reduced the incidence of neurologic complications in critically ill patients


**Clinical impact ratings:** Hospitalists ★★★★★✩✩ Critical Care ★★★★★✩✩ Neurology ★★★★★✩✩

**Question**
In critically ill patients, does intensive insulin therapy improve neurologic outcomes, including critical illness polyneuropathy (CIP)?

**Methods**
**Design:** Preplanned subgroup analyses of a randomized controlled trial of 1548 mechanically ventilated, critically ill patients.

**Allocation:** Unclear allocation concealment.*

**Blinding:** Blinded (outcome assessors).*

**Follow-up period:** Up to 12 months after discharge.

**Setting:** Surgical intensive care unit (ICU) of a hospital in Leuven, Belgium.

**Patients:** A stratified subgroup of 63 patients with isolated brain injury at baseline (mean age 57 ± 63% men) and a subgroup of 405 patients who were in the ICU for ≥ 7 days (mean age 61 ± 68% men).

**Intervention:** Intensive insulin therapy to maintain strict glycemic control between 4.4 and 6.1 mmol/L (80 and 110 mg/dL) (∗∗∗∗∗) or usual care, in which insulin therapy was recommended only when blood glucose levels were > 12 mmol/L (220 mg/dL), with the goal of maintaining levels between 10.0 and 11.1 mmol/L (180 and 200 mg/dL) (∗∗∗∗∗).

**Outcomes:** Mortality at 6 (48% vs 30%, P = 0.3) or 12 months (51% vs 30%, P = 0.2). The intensive insulin group had a shorter duration of ventilation (median 7 vs 15 d, P < 0.001) and lower intracranial pressure (peak 16 vs 19 mm Hg, P = 0.003).

**Conclusion**
In critically ill patients with prolonged ventilation or with isolated brain injury, intensive insulin therapy reduced the probabilities of further prolonged ventilation and some neurologic complications.

**Source of funding:** Belgian Foundation for Research in Congenital Heart Diseases.

*For correspondence: Dr. G. Van den Berghe, Catholic University of Leuven, Leuven, Belgium. E-mail greta.vandenbergh@med.kuleuven.ac.be.

*See Glossary.

### Commentary
Publication of the results of the trial by Van den Berghe and colleagues in 2001 (1) prompted important changes in our view of glucose management for critically ill patients. In a surgical ICU population, intensive insulin therapy (“tight control”) decreased mortality, bloodstream infections, acute renal failure, need for transfusions, and CIP. These effects were most apparent in patients who remained in the ICU for > 5 days, most of whom were general surgical patients. Many ICUs have adopted intensive insulin therapy based on these data, and other studies of various populations of critically ill patients are in progress.

The current study by Van den Berghe and colleagues is a prespecified subgroup analysis of patients who had acute central nervous system disease, primarily those with intracerebral or subarachnoid hemorrhage or those who had undergone intracranial surgery. In this group, tight control was associated with a decrease in CIP and a shorter duration of mechanical ventilation. This therapy also led to lower intracranial pressure and substantially lower vasopressor requirements to maintain cerebral perfusion pressure. ICU mortality was 18% in patients who received tight control and 23% in those who received usual care; this nonsignificant trend was reversed at 12 months of follow-up.

Most of the above argues in favor of using continuous insulin infusions to maintain tight control over blood glucose in patients with these critical neurologic illnesses, although debate on the mechanism of this effect continues (2–4). Any new therapeutic idea needs to be carefully evaluated to understand its limitations. Implementing tight control began slowly because of concerns over the possibility of causing hypoglycemia. The anecdotal experience of many centers is that hypoglycemia may actually be less common than feared, because of the frequent measurement of blood glucose. Emerging evidence of a possible interaction of tight control with disturbances of metabolism in areas of ischemic or traumatic damage deserves careful evaluation (5). On balance, however, tight control is one of the most promising advances in contemporary neurocritical care.

**References**